Why the study?
Do Angiotensin Receptor Blockers reduce fibrosis and Interleukin-6 expression in Calcific Aortic Valve Disease?
Do Angiotensin Receptor Blockers reduce fibrosis and Interleukin-6 expression in Calcific Aortic Valve Disease?
ARBs may alter the fibrotic process of the aortic valve in CAVD, possibly by lowering tissue inflammation.
Should not alter ARB use in CAVD; hypothesis-generating and requires prospective trials.
These findings suggest that ARBs may alter the fibrotic process of the aortic valve in CAVD, possibly by lowering tissue inflammation.
No takes yet. Share an insight, caveat, or question.
Côté et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: